Skip to main content
. 2019 Feb 20;13:1178223419828766. doi: 10.1177/1178223419828766

Table 1.

The patient clinicopathological data.

BCVY
Old BC
P value
NUM. % %
Age BCVY/old BC
<25 years/46-50 years 12 4.7 6 5.9
25-30 years/50-56 years 60 23.2 55 54.4
30-35 years/>65 years 186 72.1 40 39.6
Year of diagnosis
Before 2000 60 23 50 49.5 .642
After 2000 198 77 51 50.5
Tumor size
<2 cm 94 36.4 67 66.3 3.01 × 10−3
2-5 cm 112 43.4 29 28.7
>5 cm 35 13.6 5 5
Missing 17 6.6 0 0
Lymph node status
Node positive 121 46.9 38 37.6 .099
Node negative 120 46.5 59 58.4
Missing 17 6.5 4 4
Grade
I 28 11 18 17.8 .583
II 71 27.5 39 38.6
III 94 36.4 39 38.6
Missing 65 25.2 5 5
Histologic subtype
Ductal 209 81 73 72.3 .081
Lobular 10 4 7 6.9
Medullary 8 3 0 0
Tubular 6 2 4 4
Others 25 10 17 16.8
Estrogen receptor
Positive 180 70 72 71.3 .496
Negative 62 24 29 28.7
Missing 16 6 0 0
Progesterone receptor
Positive 153 59.3 69 68.3 .319
Negative 87 33.7 32 31.7
Missing 18 7 0 0
Ki 67 (%)
Low <14 20 7.7 18 17.8 .202
14-30 46 17.8 32 31.6
High >30 41 15.8 16 15.8
Missing 151a 58.5 35 34.6
Her2
Positive 73 28.3 23 22.8 .112
Negative 138 53.5 71 70.3
Missing 47b 18.2 7 6.9
Subtypes
Luminal 131 50.7 62 61.4 .651
Luminal-Her2 46 17.8 17 16.8
Her2 positive 26 10 5 5
Triple negative 35 13.5 17 16.8
Missing 20 7.5 0 0

Abbreviations: BC, breast cancer; BCVY, breast cancer in very young women.

Total number of patients: 258 BCVY and 101 old BC.

a

The data of Ki 67 were started to be used routinely in the year 2008. Previously lacking these data.

b

The data of HER2 overexpression are missing because the diagnosis is prior to the knowledge of the role of HER2 in breast cancer.

P values were obtained after a Pearson’s chi-squared test by R/Bioconductor.